Sanofi has appointed Paul Hudson as chief executive officer, effective September 1, to succeed Olivier Brandicourt who has decided to retire. The Board thanked Olivier Brandicourt for the energy with which he has steered the Group through a complex period and for his decisive contribution to the company’s return to growth. Paul Hudson most recently served as chief executive officer of Novartis Pharmaceuticals and Member of the Executive Committee of Novartis. Mr. Hudson brings int...